SHIONOGI & CO., LTD.

Filing Lawsuit against InterMune, Inc.

Osaka, Japan, July 10, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it has filed a lawsuit against InterMune, Inc. (Head Office: Brisbane, California, U.S.A; hereafter "InterMune") in the United States federal court located in San Francisco, California alleging that InterMune has failed to pay royalties to Shionogi on sales of Esbriet® (InterMune's brand name for the chemical compound pirfenidone) in the European Union as required under an Agreement for Collaboration to Exchange Documents from Clinical Studies ("Collaboration Agreement"), as amended.

In Japan, Shionogi has developed the chemical compound pirfenidone for the treatment of fibrotic diseases. In 2008, Shionogi has obtained the marketing approval and started to market pirfenidone under the name Pirespa® for the treatment of Idiopathic Pulmonary Fibrosis ("IPF"), a rare, progressive and fatal lung disease. Using Shionogi's clinical trials of pirfenidone in its Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), InterMune has obtained the MAA approval and started to market Esbriet® in the European Union for the treatment of IPF since September 2011.

Shionogi considers that, as well as any patents and other intellectual property, any data derived from our development activities for pharmaceutical products including pirfenidone is Shionogi's invaluable assets. Shionogi will continue to take appropriate measures to protect or make an effective use of such assets.

There is no effect for business performance of fiscal year 2012 by this lawsuit.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885